Michelle Carr, Author at BioTuesdays

Developments

FSD Pharma’s Dr. Eleanor Fish named to Order of Canada

Eleanor Fish, Ph.D., a member of FSD Pharma’s (NASDAQ, CSE:HUGE; FRA: 0K9A) research and clinical advisory board, was appointed to the Order of Canada for her contributions to immunology, including her ground-breaking...

January 18, 2022

Developments

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

Profound Medical (NASDAQ:PROF; TSX:PRN) treated the first patients in the Level 1 CAPTAIN trial comparing the TULSA procedure (performed with its TULSA-PRO system) against radical prostatectomy (RP). The prospective...

January 18, 2022

Executive Moves

Global medical device executive Kenneth Knudson joins Profound as CCO

Profound Medical (NASDAQ:PROF; TSX:PRN) appointed accomplished global medical device industry veteran, Kenneth Knudson, as chief commercial officer to lead Profound’s worldwide sales, marketing and reimbursement...

January 5, 2022

Developments

FSD Pharma in share repurchase program

The board of FSD Pharma (NASDAQ, CSE:HUGE; FRA: 0K9A) authorized the company to repurchase up to 2,000,000 of its subordinate Class B voting shares, or about 5% of its subordinate voting shares outstanding, from time to...

December 30, 2021

Developments

Titan Pharmaceuticals to explore strategic alternatives

Titan Pharmaceuticals (NASDAQ:TTNP) engaged Maxim Group as its exclusive financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be...

December 21, 2021

Developments

OpSens files 510(k) submission for new guidewire for TAVR procedure

OpSens (TSX:OPS; OTCQX:OPSSF) filed a 510(k) submission with the FDA for regulatory clearance of its new SavvyWire guidewire for transcatheter aortic valve replacement, or TAVR procedures. OpSens previously filed for...

December 13, 2021

Developments

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Sigyn Therapeutics (OTC: SIGY) reported that preclinical in vitro studies have validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma. Sigyn...

December 1, 2021

Developments

Clene presents updated data from RESCUE-ALS Phase 2 study

Clene (NASDAQ:CLNN) presented new data from the RESCUE-ALS Phase 2 study of CNM-Au8, a catalytically active gold nanocrystal suspension, in the treatment of amyotrophic lateral sclerosis (ALS) at the 4th annual ALS ONE...

December 1, 2021

Developments

Hepion receives FDA fast track designation for CRV431 to treat NASH

The FDA granted Hepion Pharmaceuticals (NASDAQ:HEPA) fast track designation for its lead drug candidate, CRV431, for the treatment of non-alcoholic steatohepatitis (NASH). CRV431 has been investigated in healthy...

November 30, 2021

Executive Moves

Cellares names leading bioethicist Dr. Ezekiel Emanuel to board of advisors

Closely-held cell therapy manufacturer, Cellares, appointed Ezekiel Emanuel, M.D. and Ph.D., to its board of advisors. Dr. Emanuel is a bioethicist and currently vice provost for global initiatives, the Diane and Robert...

November 16, 2021

Author - Michelle Carr

FSD Pharma’s Dr. Eleanor Fish named to Order of Canada

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

Global medical device executive Kenneth Knudson joins Profound as CCO

FSD Pharma in share repurchase program

Titan Pharmaceuticals to explore strategic alternatives

OpSens files 510(k) submission for new guidewire for TAVR procedure

Sigyn Therapeutics successfully completes study for gram-positive bacterial toxins

Clene presents updated data from RESCUE-ALS Phase 2 study

Hepion receives FDA fast track designation for CRV431 to treat NASH

Cellares names leading bioethicist Dr. Ezekiel Emanuel to board of advisors

General

More

Sign up for the BioTuesdays weekly newsletter